Sartorius Stedim Biotech (DIM) AI Stock Analysis

• Market Cap: €19.33B
• Dividend Yield: 0.35%
• Average Volume (3M): 68.91K
• Price to Earnings (P/E): 85.8
• Beta (1Y): 1.43
• Revenue Growth: 5.44%
• EPS Growth: 30.04%
• Country: FR
• Employees: 9,961
• Sector: Healthcare
• Sector Strength: 45
• Industry: Medical - Instruments & Supplies
• EPS (TTM): 1.22
• Shares Outstanding: 97,330,410
• 10 Day Avg. Volume: 87,808
• 30 Day Avg. Volume: 68,914
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): N/A
• P/FCF Ratio: N/A
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: €226.57
• Price Target Upside: 14.23% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 7

• Rating: 64 Neutral
• Price Target: €199.00 ▲(0.33% Upside)

The overall stock score of 64 reflects a solid financial performance and moderate technical indicators, but is weighed down by high valuation metrics. The company's strong profitability and stable balance sheet are positive factors, but the high P/E ratio and low dividend yield suggest the stock may be overvalued. Technical analysis shows short-term bullish momentum, but longer-term resistance. The absence of earnings call and corporate events data limits further insights.

Sartorius Stedim Biotech Business Overview & Revenue Model

Company Description

Sartorius Stedim Biotech S.A. produces and sells instruments and consumables for the biopharmaceutical industry worldwide. The company offers various products, such as cell lines; cell culture media; bioreactors; and a range of products for separation, purification, and concentration processes, as well as products and systems for storage and transportation of intermediate and finished biological products. It also provides cell cultivation, fermentation, filtration, purification, and fluid management services; single-use and reusable hollow-fiber membrane devices, as well as presterilized assemblies for cell and gene therapy applications; and cell harvesting and various other solutions for intensified bioprocesses. In addition, the company offers data analytics software for modeling and optimizing processes of biopharmaceutical development and production. It serves manufacturers of pharmaceuticals, foods, and chemicals, as well as research and development laboratories. The company was founded in 1870 and is headquartered in Aubagne, France. Sartorius Stedim Biotech S.A. is a subsidiary of Sartorius AG.

How the Company Makes Money

Sartorius Stedim Biotech generates revenue primarily through the sale of its bioprocessing equipment, consumables, and laboratory products. Key revenue streams include the direct sale of products such as single-use systems, bioreactors, and filtration devices, as well as recurring revenues from consumables associated with these systems. Additionally, the company benefits from service agreements and maintenance contracts that provide ongoing support to clients. Significant partnerships with leading pharmaceutical and biotechnology companies enhance its market reach and increase sales opportunities. The company's focus on innovation and expansion into emerging markets also contributes to its revenue growth.

Sartorius Stedim Biotech Financial Statement Overview

Summary

Sartorius Stedim Biotech demonstrates a robust financial position with strong profitability and efficient operations. The balance sheet is stable with manageable leverage, although the return on equity could be improved. Cash flow generation remains solid, but the recent decline in free cash flow growth is a concern. Overall, the company is well-positioned in its industry, but it should focus on enhancing growth and cash flow management to sustain its financial health.

Income Statement

Sartorius Stedim Biotech shows a solid performance with a TTM gross profit margin of 44.63% and a net profit margin of 7.78%. The revenue growth rate of 1.35% in the TTM indicates a stable growth trajectory, although it is lower compared to previous years. The EBIT and EBITDA margins are healthy at 14.77% and 25.55% respectively, reflecting efficient operations. However, the decline in revenue from 2022 to 2023 highlights potential challenges in maintaining growth momentum.

Balance Sheet

The company's debt-to-equity ratio has improved to 0.74 in the TTM, indicating a balanced leverage position. Return on equity is modest at 5.68%, suggesting room for improvement in generating returns for shareholders. The equity ratio stands at 48.15%, reflecting a strong equity base. The overall stability of the balance sheet is commendable, though the lower ROE is a point of concern.

Cash Flow

The operating cash flow to net income ratio of 0.83 in the TTM indicates strong cash generation relative to net income. However, the free cash flow growth rate has declined by 14.93%, signaling potential cash flow management issues. The free cash flow to net income ratio of 0.63 suggests adequate cash flow coverage, but the negative growth trend in free cash flow warrants attention.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	2.90B	2.78B	2.78B	3.49B	2.89B	1.91B
Gross Profit	1.29B	1.21B	1.23B	1.83B	1.55B	1.00B
EBITDA	739.90M	670.50M	755.70M	1.35B	811.96M	623.79M
Net Income	225.20M	175.10M	309.70M	876.10M	414.40M	335.93M
Balance Sheet
Total Assets	8.31B	8.26B	7.74B	5.07B	3.95B	3.07B
Cash, Cash Equivalents and Short-Term Investments	745.10M	688.80M	126.10M	133.00M	237.35M	69.61M
Total Debt	2.97B	2.87B	3.68B	1.14B	625.52M	586.78M
Total Liabilities	4.27B	4.23B	5.07B	2.55B	2.22B	1.59B
Stockholders Equity	4.00B	3.99B	2.64B	2.45B	1.66B	1.46B
Cash Flow
Free Cash Flow	496.50M	475.30M	156.10M	181.70M	371.98M	257.69M
Operating Cash Flow	788.10M	815.10M	629.70M	612.30M	695.97M	416.88M
Investing Cash Flow	-292.80M	-340.00M	-2.72B	-957.50M	-465.23M	-621.12M
Financing Cash Flow	-250.10M	84.90M	1.99B	220.70M	-71.71M	234.07M

Sartorius Stedim Biotech Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 198.35
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Negative
• RSI: Neutral
• STOCH: Negative

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For FR:DIM, the sentiment is Positive. The current price of 198.35 is above the 20-day moving average (MA) of 178.88, above the 50-day MA of 176.19, and above the 200-day MA of 191.32, indicating a bullish trend. The MACD of 2.76 indicates Negative momentum. The RSI at 69.07 is Neutral, neither overbought nor oversold. The STOCH value of 90.60 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for FR:DIM.

Sartorius Stedim Biotech Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
SAN	77 Outperform	$104.58B	11.75	8.39%	4.57%	-9.82%	119.10%
BIM	73 Outperform	€13.78B	36.40	9.69%	0.78%	8.28%	-8.08%
IPN	70 Outperform	€9.61B	21.46	10.82%	1.20%	9.57%	-34.30%
DIM	64 Neutral	€19.33B	85.81	5.71%	0.35%	5.44%	30.04%
ERF	64 Neutral	€11.32B	26.85	11.27%	0.97%	6.25%	18.93%
VIRP	63 Neutral	€2.66B	20.34	12.92%	0.46%	6.97%	-5.59%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%

Sartorius Stedim Biotech Corporate Events

Sartorius Stedim Biotech Releases 2024 Universal Registration Document

Sartorius Stedim Biotech has announced the availability of its 2024 Universal Registration Document, which includes the group’s business development details for 2024 and the 2025 forecast. This document, now accessible on their investor relations page, also contains the consolidated financial statements for the year ended December 31, 2024. The release of this document provides stakeholders with comprehensive insights into the company’s financial and strategic positioning, potentially impacting investor confidence and industry standing.